Clinical trials: Movement Abnormalities
Lewy Body Disease, Parkinson Disease
A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology
The purpose of study is to demonstrate the pharmacodynamic (PD) effects of E2027 on cerebrospinal fluid (CSF) cyclic guanosine monophosphate (cGMP) in participants with DLB and PDD with and without amyloid copathology after 9…
- Trial name
- NCT04764669
- Testing
- E2027
- Where
- 14 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Eisai Inc.
Wilson Disease
Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
This is a Phase 1, randomized, 2-period, 2-sequence, cross-over study designed to determine the effect of ALXN1840 on the metabolism of bupropion, a sensitive cytochrome P450 2B6 (CYP2B6) substrate, in healthy male and female…
- Trial name
- NCT04526210
- Testing
- ALXN1840, Bupropion Hydrochloride
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Parkinson Disease
Safety and Efficacy of Liraglutide in Parkinson's Disease
The purpose of this study is to test the efficacy and safety of liraglutide in the treatment of patients with idiopathic Parkinson's disease (PD).
- Trial name
- NCT02953665
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Cedars-Sinai Medical Center
Dementia, Cognitive Dysfunction
A Relational Research Recruitment and Engagement Intervention for Cognitive Aging Research
Despite well-documented disparities in Alzheimer's disease and related dementia (AD) prevalence, incidence, treatment, and mortality, individuals from disadvantaged backgrounds (e.g.
- Conditions
- Dementia, Cognitive Dysfunction, Alzheimer Disease, Lewy Body Disease
- Trial name
- NCT05444244
- Testing
- Relational Research Recruitment and Engagement Intervention
- Where
- United States
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Tardive Dyskinesia
NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 (titrated to a subject's optimal dose in the range of 25 to 75 mg) administered once daily for the treatment of Tardive Dyskinesia (TD)…
- Trial name
- NCT01733121
- Testing
- NBI-98854
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 102 people
- Sponsor
- Neurocrine Biosciences
Akathisia, Drug-Induced, Dyskinesia, Drug-Induced
Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)
This study was designed to determine if preladenant (SCH 420814, MK-3814) can reduce drug-induced involuntary movements in participants with schizophrenia or schizoaffective disorder.
- Conditions
- Akathisia, Drug-Induced, Dyskinesia, Drug-Induced, Parkinsonian Disorders
- Trial name
- NCT00686699
- Testing
- Preladenant
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Pure Autonomic Failure
Nebivolol in the Supine Hypertension of Autonomic Failure
The purpose of this study is to evaluate the effect of the antihypertensive drug, nebivolol (Bystolic), compared to metoprolol (Lopressor) and sildenafil (Viagra) on blood pressure in patients with autonomic failure and supine…
- Conditions
- Hypertension, Pure Autonomic Failure, Multiple System Atrophy
- Trial name
- NCT01044693
- Testing
- Nebivolol 5 mg, metoprolol tartrate 50 mg, Sildenafil25 mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University
Chorea
First Time Use of SD-809 in Huntington Disease
The purpose of this study is to determine whether SD-809 tablets are effective in the treatment of chorea associated with Huntington's Disease.
- Trial name
- First-HD (NCT01795859)
- Testing
- SD-809
- Where
- 43 sites in United States, Australia and 1 more
- Volunteers
- 90 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Dementia With Lewy Bodies, REM Sleep Behavior Disorder
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
This study seeks to evaluate the safety and efficacy of Nelotanserin for the treatment of Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with dementia with Lewy bodies (DLB) or Parkinson's disease dementia…
- Conditions
- Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Parkinson's Disease Dementia
- Trial name
- NCT02708186
- Testing
- Nelotanserin
- Where
- 23 sites in United States
- Volunteers
- 34 people
- Sponsor
- Axovant Sciences Ltd.
Parkinson Disease
Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
The objective of this PMS study is the evaluation of depressive symptoms measured with Unified Parkinson's Disease Rating Scale (UPDRS) Part I (mentation, behavior and mood) and with Hospital Anxiety and Depression Scale…
- Trial name
- NCT00651183
- Testing
- Pramipexole immediate release
- Where
- 57 sites in Austria
- Volunteers
- 286 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of immediate-release levodopa/benserazide 100/25 mg…
- Trial name
- NCT02169895
- Testing
- BIA 9-1067, Prolopa®
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease, Motor Disorder
BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and efficacy of BTRX-246040 in participants with Parkinson's Disease who have motor fluctuations and predictable early morning off periods.
- Trial name
- NCT03608371
- Testing
- BTRX-246040
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- BlackThorn Therapeutics, Inc.
Parkinsons Disease
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on…
- Trial name
- PADOVA (NCT04777331)
- Testing
- Prasinezumab
- Where
- 110 sites in United States, Austria and 7 more
- Volunteers
- 586 people
- Sponsor
- Hoffmann-La Roche
Parkinson Disease
Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease
Post-marketing surveillance (PMS) to investigate the safety and efficacy of long-term daily use of Mirapex®-LA Tablets in patients with Parkinson's disease.
- Trial name
- NCT01525641
- Testing
- Mirapex LA
- Where
- 118 sites in Japan
- Volunteers
- 615 people
- Sponsor
- Boehringer Ingelheim
Tardive Dyskinesia (TD)
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the potential for clinical dependence and withdrawal symptoms associated with valbenazine.
- Trial name
- NCT03698331
- Testing
- Valbenazine
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 89 people
- Sponsor
- Neurocrine Biosciences
Tourette Syndrome
Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome
Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 8 weeks of treatment.
- Trial name
- NCT02581865
- Testing
- NBI-98854
- Where
- 30 sites in United States
- Volunteers
- 124 people
- Sponsor
- Neurocrine Biosciences
Parkinson's Disease
Study of Magnetic Fields for Treatment of Parkinson's Disease
The purpose of this study is to determine if low level magnetic fields may help to relieve symptoms of Parkinson's disease.
- Trial name
- NCT00779155
- Testing
- The Resonator, The Resonator control
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- pico-tesla Magnetic Therapies, LLC
Parkinson Disease, Essential Tremor
Analysis and Suppression of Tremor During Grasp Using Ultrasound Imaging and Electrical Stimulation
Individuals experiencing tremors face difficulty performing activities of daily living caused by involuntary oscillation of the muscles in the hands and arms.
- Trial name
- Tremor (NCT05308368)
- Testing
- Ultrasound Imaging, Electromyography, Inertial Measurement Units (IMU)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- North Carolina State University
Parkinson Disease
Effect of Levodopa on Postural Motor Learning in Parkinson Disease
The primary goal of this project is to gain a better understanding of whether and how levodopa (a common anti-Parkinson disease medication) alters postural motor learning in people with Parkinson disease.
- Trial name
- NCT02239978
- Testing
- Postural perturbation
- Where
- 3 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Essential Voice Tremor, Vocal Tremor
Effects of Octanoic Acid for Treatment of Essential Voice Tremor
Essential voice tremor is a neurological condition that produces a regular, shaking quality in the voice. One form of drug treatment that produces some improvement in tremor of the hands is octanoic acid, which is a food additive…
- Conditions
- Essential Voice Tremor, Vocal Tremor, Voice Tremor, Essential Tremor of Voice
- Trial name
- NCT01864525
- Testing
- Octanoic acid, Inactive capsule
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Syracuse University